Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and HER2 BATs in mCRPC
NCT03406858Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jun 2018
- Primary completion
- Jan 2021
- Modality
- Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of HER2Bi-armed activated T cells in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Barbara Ann Karmanos Cancer Institute. Started Jun 2018; status: completed.
02
Drugs
HER2Bi-armed activated T cells
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03406858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406858.